Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [41] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
    Nanni, Jacopo
    Papayannidis, Cristina
    Cristiano, Gianluca
    Marconi, Giovanni
    Sartor, Chiara
    Parisi, Sarah
    Ottaviani, Emanuela
    Baldini, Lorenza
    Testoni, Nicoletta
    Baldazzi, Carmen
    Ricci, Paolo
    Bezzi, Chiara Di Giovanni
    Abd-alatif, Rania
    Paolini, Stefania
    Cavo, Michele
    Curti, Antonio
    BLOOD, 2020, 136
  • [42] Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Sri
    Pandya, Vishruti
    Bae, Sejong
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly Nicole
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna E.
    Di Stasi, Antonio
    Vachhani, Pankit
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18808 - E18808
  • [43] Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies
    Goldberg, Aaron D.
    Horvat, Troy Z.
    Hsu, Meier
    Devlin, Sean M.
    Cuello, Bernadette M.
    Daley, Ryan J.
    King, Amber C.
    Buie, Larry W.
    Glass, Jacob L.
    Mauro, Michael J.
    Stein, Eytan M.
    Berman, Ellin
    Klimek, Virginia M.
    Tallman, Martin S.
    BLOOD, 2017, 130
  • [44] Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Pillai, Raju
    Shouse, Geoffrey
    Sanchez, James F.
    Mei, Matthew
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) : E45 - E48
  • [45] VENETOCLAX AND HYPOMETHYLATING AGENTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE-CENTRE EXPERIENCE
    Dreisinger, M.
    Roskar, Z.
    ANNALS OF HEMATOLOGY, 2023, 102 (SUPPL 1) : S54 - S54
  • [46] 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
    DiNardo, Courtney D.
    Maiti, Abhishek
    Rausch, Caitlin R.
    Pemmaraju, Naveen
    Naqvi, Kiran
    Daver, Naval G.
    Kadia, Tapan M.
    Borthakur, Gautam
    Ohanian, Maro
    Alvarado, Yesid
    Issa, Ghayas C.
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias J.
    Takahashi, Koichi
    Burger, Jan A.
    Garcia-Manero, Guillermo
    Jain, Nitin
    Kornblau, Steven M.
    Thompson, Philip A.
    Estrov, Zeev
    Masarova, Lucia
    Sasaki, Koji
    Verstovsek, Srdan
    Ferrajoli, Alessandra
    Weirda, William G.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Ravandi, Farhad
    Andreeff, Michael
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    LANCET HAEMATOLOGY, 2020, 7 (10): : E724 - E736
  • [47] Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
    Chantepie, Sylvain P.
    Reboursiere, Emilie
    Mear, Jean-Baptiste
    Gac, Anne-Claire
    Salaun, Veronique
    Benabed, Khaled
    Cheze, Stephane
    Johnsonansah, Hyacinthe
    Macro, Margaret
    Vilque, Jean-Pierre
    Reman, Oumedaly
    LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2326 - 2330
  • [48] Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Shahswar, Rabia
    Beutel, Gernot
    Gabdoulline, Razif
    Schwarzer, Adrian
    Kloos, Arnold
    Koenecke, Christian
    Stadler, Michael
    Goehring, Gudrun
    Schlegelberger, Brigitte
    Li, Zhixiong
    Dallmann, Louisa-Kristin
    Wienecke, Clara
    Klement, Piroska
    Albert, Catherin
    Wichmann, Martin
    Alwie, Yasmine
    Benner, Axel
    Saadati, Maral
    Ganser, Arnold
    Thol, Felicitas R.
    Heuser, Michael
    BLOOD, 2022, 140 : 3315 - 3316
  • [49] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
    Bouligny I.M.
    Murray G.
    Doyel M.
    Patel T.
    Boron J.
    Tran V.
    Gor J.
    Hang Y.
    Alnimer Y.
    Ho T.
    Zacholski K.
    Venn C.
    Wages N.A.
    Grant S.
    Maher K.R.
    Medical Oncology, 41 (3)
  • [50] Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
    Brancati, Serena
    Gozzo, Lucia
    Romano, Giovanni Luca
    Vetro, Calogero
    Dulcamare, Ilaria
    Maugeri, Cinzia
    Parisi, Marina
    Longo, Laura
    Vitale, Daniela Cristina
    Di Raimondo, Francesco
    Drago, Filippo
    BLOOD, 2021, 138
12345